Profile data is unavailable for this security.
About the company
Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
- Revenue in SEK (TTM)28.24bn
- Net income in SEK478.00m
- Incorporated1939
- Employees1.89k
- LocationSwedish Orphan Biovitrum AB (publ)Norra Stationsgatan 93ASTOCKHOLM 112 76SwedenSWE
- Phone+46 86972000
- Websitehttps://www.sobi.com/
More ▼
Mergers & acquisitions
| Acquired company | SOBI:STO since announced | Transaction value |
|---|---|---|
| Pharma Investments SA | 24.47% | -- |
| Pint Pharma International Ltd | 42.34% | -- |
Data delayed at least 15 minutes, as of Mar 02 2026 17:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | 4.53bn | -6.55bn | 116.37bn | 834.00 | -- | -- | -- | 25.67 | -3.78 | -3.78 | 2.62 | -10.71 | 0.5412 | -- | 6.97 | 602,009.60 | -79.01 | -76.52 | -105.26 | -96.54 | 95.82 | 96.16 | -145.98 | -340.73 | 2.68 | -2.17 | 4.29 | -- | 126.26 | 127.44 | -35.31 | -- | 4.99 | -- |
| Elanco Animal Health Inc | 42.57bn | -2.09bn | 118.51bn | 9.40k | -- | 2.00 | 29.30 | 2.78 | -0.4848 | -0.4848 | 9.53 | 13.17 | 0.3631 | 1.28 | 5.62 | 501,595.80 | -1.79 | -2.26 | -2.01 | -2.53 | 54.99 | 55.59 | -4.92 | -7.41 | 1.08 | 1.15 | 0.3803 | -- | 6.22 | 7.59 | -168.64 | -- | -2.35 | -- |
| Neurocrine Biosciences Inc | 25.83bn | 4.32bn | 119.85bn | 2.00k | 28.36 | 4.07 | 26.09 | 4.64 | 4.66 | 4.66 | 27.91 | 32.50 | 0.6851 | 0.8244 | 4.91 | 1,430,250.00 | 11.46 | 9.00 | 13.48 | 10.78 | 98.18 | 98.32 | 16.73 | 13.51 | 3.30 | -- | 0.00 | -- | 21.45 | 22.29 | 40.23 | 3.28 | 25.55 | -- |
| Zhangzhou Pientzhng Phrmctcl Co Ltd | 12.88bn | 3.19bn | 129.67bn | 2.84k | 40.70 | 6.81 | -- | 10.07 | 4.01 | 4.01 | 16.21 | 23.99 | 0.5515 | 1.15 | 11.11 | 3,444,842.00 | 13.60 | 18.53 | 16.58 | 23.24 | 36.98 | 45.91 | 24.65 | 28.42 | 2.12 | -- | 0.0658 | 42.26 | 7.25 | 13.52 | 6.42 | 16.72 | 74.81 | 29.36 |
| Sino Biopharmaceutical Ltd | 40.35bn | 5.15bn | 131.01bn | 23.06k | 24.49 | 2.84 | 12.21 | 3.25 | 0.247 | 0.2453 | 1.93 | 2.13 | 0.4317 | 2.83 | 3.98 | 1,433,824.00 | 9.56 | 12.16 | 18.52 | 20.91 | 81.77 | 80.75 | 22.15 | 26.50 | 1.28 | -- | 0.2071 | 27.19 | 10.18 | 3.56 | 3.93 | -7.01 | -7.91 | 6.66 |
| CSPC Pharmaceutical Group Ltd | 34.60bn | 5.36bn | 131.67bn | 19.27k | 24.41 | -- | 53.28 | 3.81 | 0.4056 | 0.4056 | 2.61 | -- | -- | -- | -- | 1,400,839.00 | -- | 14.64 | -- | 19.49 | 66.23 | 72.50 | 15.54 | 19.11 | -- | -- | -- | 41.10 | -7.76 | 5.59 | -26.31 | 3.11 | 4.76 | 21.28 |
| Swedish Orphan Biovitrum AB (publ) | 28.24bn | 478.00m | 141.32bn | 1.89k | 304.90 | 3.62 | 35.69 | 5.00 | 1.30 | 1.30 | 81.42 | 109.12 | 0.3953 | 1.28 | 5.11 | 14,956,040.00 | 0.6663 | 3.92 | 0.8337 | 5.04 | 78.89 | 77.84 | 1.69 | 10.91 | 0.585 | 9.61 | 0.2336 | 0.00 | 8.50 | 13.10 | -87.70 | -31.82 | -3.93 | -- |
| Sichuan Biokin Pharmaceutical Co Ltd | 2.93bn | -1.12bn | 143.83bn | 2.52k | -- | 15.23 | -- | 49.08 | -2.14 | -2.14 | 5.54 | 17.37 | 0.2309 | 1.44 | 2.31 | 883,003.90 | -8.84 | 27.12 | -11.31 | 47.59 | 89.15 | 86.86 | -38.29 | 29.03 | 5.23 | -- | 0.3446 | 0.00 | 936.31 | 37.00 | 575.02 | 243.69 | 31.86 | -- |
| Torrent Pharmaceuticals Ltd | 12.63bn | 2.25bn | 145.40bn | 16.11k | 64.56 | -- | 47.55 | 11.51 | 67.12 | 67.12 | 376.38 | -- | -- | -- | -- | 7,910,902.00 | -- | 9.54 | -- | 14.72 | 75.64 | 72.56 | 17.83 | 14.14 | -- | 16.34 | -- | 61.09 | 7.35 | 7.72 | 15.39 | 14.48 | 8.51 | 30.36 |
| Ipsen SA | 41.91bn | 4.73bn | 147.61bn | 5.36k | 31.04 | 3.15 | 14.30 | 3.52 | 5.32 | 5.32 | 47.09 | 52.42 | 0.5875 | 2.85 | 5.30 | -- | 6.66 | 9.15 | 8.54 | 12.07 | 80.89 | 82.61 | 11.33 | 15.86 | 1.79 | 122.28 | 0.1845 | 20.03 | 9.92 | 7.90 | 24.61 | -4.01 | 18.50 | 6.96 |
| Viatris Inc | 127.54bn | -33.33bn | 155.22bn | 32.00k | -- | 1.14 | -- | 1.22 | -3.10 | -3.10 | 11.96 | 13.13 | 0.3417 | 2.09 | 4.90 | 441,387.50 | -8.93 | -0.1756 | -10.89 | -0.2096 | 39.36 | 40.66 | -26.13 | -0.5768 | 0.793 | 2.79 | 0.4868 | -- | -4.46 | 5.09 | -1,259.42 | -- | -3.10 | -- |
| Divi's Laboratories Ltd | 10.23bn | 2.46bn | 168.67bn | 18.30k | 68.58 | -- | 58.08 | 16.49 | 93.45 | 93.45 | 388.82 | -- | -- | -- | -- | 5,636,066.00 | -- | 15.81 | -- | 17.33 | 61.65 | 55.90 | 24.04 | 25.82 | -- | -- | -- | 35.19 | 19.31 | 11.65 | 36.94 | 9.74 | 3.98 | 13.40 |
| Innovent Biologics Inc | 15.08bn | 1.49bn | 170.45bn | 6.19k | 110.26 | 8.53 | 79.74 | 11.30 | 0.7718 | 0.7718 | 7.85 | 9.97 | 0.5205 | 1.80 | 7.39 | 2,308,311.00 | 5.16 | -8.71 | 6.52 | -10.73 | 85.69 | 84.74 | 9.91 | -24.84 | 2.39 | -- | 0.1898 | -- | 51.82 | 55.17 | 90.79 | -- | 35.02 | -- |
Data as of Mar 02 2026. Currency figures normalised to Swedish Orphan Biovitrum AB (publ)'s reporting currency: Swedish Krona SEK
20.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 Dec 2024 | 20.76m | 5.81% |
| Swedbank Robur Fonder ABas of 30 Jan 2026 | 13.90m | 3.89% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 7.17m | 2.01% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 6.50m | 1.82% |
| AMF Fonder ABas of 30 Jun 2025 | 6.50m | 1.82% |
| Nordea Investment Management ABas of 31 Dec 2025 | 4.82m | 1.35% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 3.45m | 0.97% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 3.41m | 0.95% |
| Lannebo Kapitalf�rvaltning AB (Sweden)as of 31 Dec 2025 | 2.75m | 0.77% |
| SEB Funds ABas of 30 Jan 2026 | 2.64m | 0.74% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
